Top Markets
#1 Black Phoenix Black Phoenix +166.18%
#2 Islamic Coin Islamic Coin +158.21%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.80%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.53%
#6 MarsCoin MarsCoin +13.34%
#7 Test Test +12.58%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.52%
#9 Palladium Network Palladium Network +9.76%
#10 Useless Coin Useless Coin +9.21%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Rang in aandelen #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Aandeelprijs
$0.0005
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$10.28K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel VIA Pharmaceuticals, Inc. (VIAP)

Categorie

Healthcare
Operationele marge voor VIA Pharmaceuticals, Inc. (VIAP)
Operationele marge op 2026 TTM: 0.00%
Volgens de meest recente financiële rapporten en aandelenkoers van VIA Pharmaceuticals, Inc. is de huidige operationele marge (TTM) 0.00%. Eind 2026 had het bedrijf een operationele marge van 0.00%.
Geschiedenis van de operationele marge van VIA Pharmaceuticals, Inc. van 2026 tot 2026
Operationele marge aan het einde van elk jaar
Jaar Operationele Marge Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Operationele marge van vergelijkbare bedrijven of concurrenten
Bedrijf Operationele Marge Verschil in operationele marge Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
67.93% -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00% -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00% -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00% -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.77% -
US
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.